Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corona RemediesBOM:544644 +0.73%18 EV-to-FCF is 1,011.39 as of Aug. 08, 2026, which is 27% above its 10-year median of 799.36. GuruFocus rates BOM:544644 with a GF Score™ of 18/100. The stock has 4 warning signs investors should review. Among 569 Drug Manufacturers companies, Corona Remedies ranks worse than 98.59% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Corona Remedies's Enterprise Value is ₹127,547 Mil.
Corona Remedies's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was ₹126 Mil. Therefore, Corona Remedies's EV-to-FCF for today is 1,011.39.
The historical rank and industry rank for Corona Remedies's EV-to-FCF or its related term are showing as below:
BOM:544644'
s EV-to-FCF Range Over the Past 10 Years
Min: 671.96 Med: 799.36 Max: 1029.77
Current: 1029.77
During the past 4 years, the highest EV-to-FCF of Corona Remedies was 1029.77. The lowest was 671.96. And the median was 799.36.
BOM:544644's EV-to-FCF is ranked worse than 98.59% of 569
companies
in the Drug Manufacturers industry
Industry Median: 21.6
vs BOM:544644: 1029.77
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Corona Remedies's PE Ratio (TTM) for today is calculated as:
Corona Remedies's share price for today is ₹2060.95.
Corona Remedies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹23.990.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Corona Remedies EV-to-FCF Related Terms
Corona Remedies EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Corona Remedies's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544644 vs LLY, JNJ, ABBV: EV-to-FCF Comparison
For the Drug Manufacturers - General subindustry, Corona Remedies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corona Remedies EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Corona Remedies's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Corona Remedies's EV-to-FCF falls into.
Corona Remedies's current Enterprise Value is ₹127,547 Mil.
Corona Remedies's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹126 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corona Remedies (BOM:544644) has a EV-to-FCF of 1,011.39 as of Aug. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Corona Remedies and its competitors. This is 27% above median its historical median of 799.36. Over the past decade, Corona Remedies' EV-to-FCF has ranged from 671.96 to 1,029.77. According to the industry distribution chart, Corona Remedies ranks #561 out of 569 companies in the Drug Manufacturers industry, placing it in the top 98.6%.
Is Corona Remedies' EV-to-FCF too high?
Corona Remedies' current EV-to-FCF of 1,011.39 is 27% above median its 10-year median of 799.36. Over the past 10 years, this metric has ranged from a low of 671.96 to a high of 1,029.77. The Drug Manufacturers industry median EV-to-FCF is 21.60. Corona Remedies' value of 1,011.39 is 4582.4% above this industry median. Based on the distribution chart, Corona Remedies ranks #561 out of 569 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Corona Remedies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Corona Remedies' EV-to-FCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Corona Remedies ranks #561 out of 569 companies for EV-to-FCF. This places Corona Remedies in the lower half of its industry. The industry median EV-to-FCF is 21.60. Corona Remedies' value of 1,011.39 is 4582.4% above this benchmark. Historically, Corona Remedies' own EV-to-FCF has ranged from 671.96 to 1,029.77 over the past decade. While the company's 10-year median is 799.36 vs. the industry median of 21.60, Corona Remedies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.60, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corona Remedies's current EV-to-FCF of 1,011.39 is 4582.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Corona Remedies and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corona Remedies's current EV-to-FCF is 1,011.39, which is 27% above median its own 10-year median of 799.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corona Remedies stock overvalued right now?
Corona Remedies (BOM:544644) has a current EV-to-FCF of 1,011.39. The current EV-to-FCF is 1,011.39, which is 27% above median its 10-year median of 799.36 and 4582.4% above the Drug Manufacturers industry median of 21.60. Corona Remedies' overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Corona Remedies (BOM:544644), the current EV-to-FCF is 1,011.39 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. It is engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabetes, pain management, urology and other segments, such as Vitamin Minerals and Nutrients(VMN), gastrointestinal and respiratory therapies. The company's brands are B-29, myoril, Tricium, Cortel, and Obimet. The Company has only one reportable business segment i.e. Pharmaceuticals. The company has presence in India as well as Outside India. The company generates majority of revenue from India.
18GF Score
Get the complete analysis for BOM:544644
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544644 has been successfully added to your 
